Thalia S Field, Vanessa Dizonno, Mohammed A Almekhlafi, Fouzi Bala, Ibrahim Alhabli, Hubert Wong, Monica Norena, Maria Karina Villaluna, Princess King-Azote, Namali Ratnaweera, Steven Mancini, Stephen C Van Gaal, Laura K Wilson, Brett R Graham, Luciano A Sposato, Dylan Blacquiere, Brian M Dewar, Mark I Boulos, Brian H Buck, Celine Odier, Kanjana S Perera, Aleksandra Pikula, Aleksander Tkach, George Medvedev, Carolyn Canfield, W Ben Mortenson, Janel O Nadeau, Sohaila Alshimemeri, Oscar R Benavente, Andrew M Demchuk, Dar Dowlatshahi, Sylvain Lanthier, Agnes Y Y Lee, Jennifer Mandzia, Deepa Suryanarayan, Jeffrey I Weitz, Michael D Hill
BACKGROUND: Emerging data suggest that direct oral anticoagulants may be a suitable choice for anticoagulation for cerebral venous thrombosis (CVT). However, conducting high-quality trials in CVT is challenging as it is a rare disease with low rates of adverse outcomes such as major bleeding and functional dependence. To facilitate the design of future CVT trials, SECRET (Study of Rivaroxaban for Cerebral Venous Thrombosis) assessed (1) the feasibility of recruitment, (2) the safety of rivaroxaban compared with standard-of-care anticoagulation, and (3) patient-centered functional outcomes...
September 7, 2023: Stroke; a Journal of Cerebral Circulation